Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer

Neoplasia

Volumn 13, Issue 5, 2011, Pages 453-460

  Liu, Yanning ^a   Norton, John T ^b   Witschi, Mark A ^c   Xu, Qun ^c   Lou, Guohua ^a   Wang, Chen ^b   Appella, Daniel H ^c   Chen, Zhi ^a   Huang, Sui ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINO NUMONAFIDE; 6 METHOXYETHYLAMINO NUMONAFIDE; AMONAFIDE; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; FECES ANALYSIS; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; LONG TERM CARE; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SHORT COURSE THERAPY; STOMACH CANCER; SURVIVAL RATE; TREATMENT INDICATION; WEIGHT CHANGE;

EID: 79955819482     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101738     Document Type: Article

References (15)

1. Lv M and Xu H (2009). Overview of naphthalimide analogs as anticancer agents. Curr Med Chem 16(36), 4797-4813.
2. Ingrassia L, Lefranc F, Kiss R, and Mijatovic T (2009). Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem 16(10), 1192-1213.
3. Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, and Lyss AP (1995). Amonafide: an active agent in the treatment of previously untreated advanced breast cancer-a Cancer and Leukemia Group B study (CALGB 8642). Clin Cancer Res 1(7), 699-704.
4. Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, and Budman DR (2010). Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leuk Res 34(4), 487-491.
5. Witschi MA, Luong L, Kawamura A, Ghosh S, Stack MS, Sim E, Avram MJ, Appella DH, and Huang S (2008). Synthesis and anticancer activities of 6-amino amonafide derivatives. Anticancer Drugs 19(1), 23-36.
6. Du P, Kibbe WA, and Lin SM (2008). Lumi: a pipeline for processing Illumina microarray. Bioinformatics 24(13), 1547-1548.
7. Lin SM, Du P, Huber W, and Kibbe WA (2008). Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36(2), e11.
8. Du P, Kibbe WA, and Lin SM (2007). Nuid: a universal naming scheme of oligonucleotides for Illumina, Affymetrix, and other microarrays. Biol Direct 2, 16.
9. Wettenhall JM and Smyth GK (2004). Limmagui: a graphical user interface for linear modeling of microarray data. Bioinformatics 20(18), 3705-3706.
10. Clifford B, Beljin M, Stark GR, and Taylor WR (2003). G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 63(14), 4074-4081.
11. Van Quaquebeke E, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, El Yazidi M, et al. (2007). 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem 50(17), 4122-4134.
12. Mijatovic T, Mahieu T, Bruyere C, De Neve N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, and Bontempi G (2008). UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia 10(6), 573-586.
13. Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, and Nakao A (2009). Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol 35(3), 477-483.
14. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, Formelli F, Pilotti S, Pierotti MA, and Greco A (2008). Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 88(5), 474-481.
15. Igal RA (2010). Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis 31(9), 1509-1515.